Cipla partners with Qilu to license, supply Keytruda biosimilar in US

1693926768 8959



Cipla’s US subsidiary Invagen Pharmaceuticals will market Qilu Pharmaceutical’s QL2107, a biosimilar to Merck’s cancer drug Keytruda, in the United States



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *